ClinicalTrialsFinder
RecruitingPhase 2NCT07452250

Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases

A Single-center, Evaluator-blinded Clinical Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Magnetic Resonance Venography in Patients With Venous System Diseases

Sponsor

Min Zhou

Enrollment

50 participants

Start Date

Mar 8, 2026

Study Type

INTERVENTIONAL

Conditions

Venous Diseases

Summary

The purpose of this single-center, prospective, evaluator-blinded study is to establish and optimize the imaging protocol for ferumoxytol-enhanced magnetic resonance venography (Fe-MRV) in patients with venous system diseases. Current gadolinium-based contrast agents used in MRI have limitations, including short circulation half-lives and potential risks for patients with renal impairment. Ferumoxytol, a superparamagnetic iron oxide nanoparticle, offers a longer imaging window and no renal toxicity, making it a promising alternative for vascular imaging. This study will enroll 50 adult patients with suspected or confirmed venous structural abnormalities or circulation disorders. To determine the minimum effective diagnostic dose, each participant will receive a total dose of 3.0 mg/kg, administered as four equal intravenous aliquots, with MRI performed after each aliquot (cumulative doses: 0.75, 1.50, 2.25, and 3.0 mg/kg). Independent, blinded radiologists will evaluate the image quality at each cumulative dose level to determine the lowest possible dose required to achieve successful clinical diagnosis.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age \>= 18 years.
  • Suspected or preliminarily diagnosed venous structural abnormalities (e.g., lower-extremity veins, central veins) or venous circulation disorders requiring Fe-MRV evaluation.
  • Able and willing to provide written informed consent.

Exclusion Criteria8

  • History of allergy/hypersensitivity to iron or dextran, or known allergy-prone constitution.
  • Currently receiving other oral or intravenous iron products.
  • Hemosiderosis or hemochromatosis.
  • Prior hypersensitivity reaction to intravenous iron products, or any condition associated with iron overload.
  • Unable to undergo MRI for psychological reasons (e.g., claustrophobia) or physical reasons (e.g., non-MRI-compatible metallic implants/foreign bodies).
  • End-stage disease or life expectancy \< 1 year.
  • Pregnant women.
  • Any other condition judged by the investigator to make the participant unsuitable for the study.
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFerumoxytol injection

Ferumoxytol is a superparamagnetic iron oxide nanoparticle contrast agent. It is administered intravenously at a total dose of 3.0 mg/kg, divided into four equal consecutive aliquots (0.75 mg/kg each).

Locations(1)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07452250